A PD-1 antibody, nivolumab, a fully human immunoglobulin (Ig) G4 monoclonal antibody targeting PD-1, has been approved for the third line and later treatment for advanced gastric cancer patients, based on the results of a phase III randomized clinical trial, ATTRACTION-22, which. This evidence concerns the gene PDCD1 and gastric cancer.